Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Recruiting 2Unknown 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 8Multiple Myeloma 2Carcinoma, Ovarian Epithelial 2Recurrence 1Peritoneal Neoplasms 1Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Breast Neoplasms 1Advanced Solid Tumor 1Advanced Ovarian Cancer 1Advanced Malignancies 1

Interventions

Carboplatin 87Paclitaxel 77Bevacizumab 38Topotecan 23liposomal doxorubicin 22Gemcitabine 22Taxes 21Cisplatin 17Drug Therapy 14Docetaxel 14Cyclophosphamide 14pembrolizumab 13Immunoglobulin G 12Disulfides 12veliparib 8rucaparib 8mirvetuximab soravtansine 8niraparib 7Albumin-Bound Paclitaxel 7sargramostim 6Filgrastim 6Erlotinib Hydrochloride 6Doxorubicin 6pazopanib 5Granulocyte-Macrophage Colony-Stimulating Factor 5Chemotherapy, Adjuvant 5CP protocol 5trebananib 4temsirolimus 4olaparib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Fallopian Tube Neoplasms × 1-dodecylpyridoxal × Clear all
NCT05483933 2025-12-23

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Shattuck Labs, Inc.

Phase 1 Completed
86 enrolled 17 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡